Market Overview

TherapeuticsMD Shares Rally +27% On FBR's Initiation

18 Stocks Moving In Monday's Pre-Market Session
Watch These 5 Huge Put Purchases In Wednesday Trade
TherapeuticsMD Soars On Positive Menopause Drug Trial Results (Investor's Business Daily)

Shares of TherapeuticsMD (NYSE: TXMD) gained 27.6 percent following FBR's initiation. FBR analyst William Tanner initiated coverage on TherapeuticsMD with an Outperform rating and $34.00 price target.

Tanner reported that TherapeuticsMD's TX-001 is likely the only FDA approved bio-identical hormone formulation. The analyst added that the formulation could even change the way women are treated with hormone replacement therapy. FBR emphasized that the company is truly a “big deal” in regards to women's health.

The analyst further noted that TherapeuticsMD may attract a large pharma partner.

Shares of TherapeuticsMD closed at $4.13 on Monday. The stock gained 27.6 percent to $5.27 before seeing some selloff. The stock is currently up 24.4 percent.

Latest Ratings for TXMD

Nov 2016OppenheimerInitiates Coverage OnOutperform
Nov 2016GuggenheimAssumesBuy
Apr 2016Goldman SachsInitiates Coverage onBuy

View More Analyst Ratings for TXMD
View the Latest Analyst Ratings

Posted-In: FBRAnalyst Color Health Care Price Target Initiation Hot Analyst Ratings General


Related Articles (TXMD)

View Comments and Join the Discussion!